Armando Corona received his B.S. in Chemistry from the University of North Carolina at Pembroke. Here, he was part of various research projects in the chemistry department finding more effective methods to produce biodiesel from used cooking oil. After completing his B.S. Degree, Armando spent one year at The University of North Carolina at Chapel Hill testing anti-Notch signaling antibodies to target aggressive kidney cancer. Armando received his Ph.D. in Pharmacology and Cancer Biology from Duke University. His doctoral research focused on identifying regulators of the TGF-β signaling pathway in metastatic breast cancer cells.
Armando has a diverse scientific background including molecular biology methods such as cell culture, genetically engineered mouse modeling, cellular cloning, proteomics, next generation sequencing, testing cancer cell metastasis potential and cellular signaling.
Prior to joining Myers Bigel, Armando worked as a technical specialist, where he assisted in patentability, validity, infringement, and freedom-to-operate analyses; and as a technology transfer fellow, where he met with inventors to discuss the detailed nature of their inventions, identified potential disclosures that could challenge patentability, performed prior art analyses, and assessed the marketability of inventions. Armando is registered to practice before the U.S. Patent and Trademark Office.